Cue Biopharma, Inc.

NasdaqCM:CUE Stock Report

Market Cap: US$26.0m

Cue Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Oz Azam

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage9.69%
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3.2yrs

Recent management updates

Recent updates

Is Cue Biopharma (NASDAQ:CUE) Using Debt In A Risky Way?

Oct 09
Is Cue Biopharma (NASDAQ:CUE) Using Debt In A Risky Way?

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

CEO Compensation Analysis

How has Oz Azam's remuneration changed compared to Cue Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$1mUS$143k

-US$27m

Compensation vs Market: Oz's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD609.16K).

Compensation vs Earnings: Insufficient data to compare Oz's compensation with company performance.

CEO

Oz Azam (56 yo)

less than a year
Tenure
US$1,476,515
Compensation

Dr. Usman Azam, also known as Oz, M.D., serves as Chief Executive Officer and Director of Inspirna, Inc. since May 2023. He served as Chief Executive Officer and President since September 29, 2025 at Cue B...

Leadership Team

NamePositionTenureCompensationOwnership
Usman Azam
Presidentless than a yearUS$1.48mno data
Lucinda Warren
Principal Financial & Accounting Officerless than a yearUS$801.22kno data
Colin Sandercock
Senior VP8.3yrsUS$599.22kno data
Ronald Seidel
Co-Founderno dataUS$316.63kno data
Rodolfo Chaparro
Co-Founderno dataUS$316.63kno data
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Boardno datano datano data
Daniel Baker
Interim Chief Development Officer1.3yrsno datano data
0.9yrs
Average Tenure
56yo
Average Age

Experienced Management: CUE's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Usman Azam
Presidentno dataUS$1.48mno data
Steven Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board11.2yrsno datano data
Frank Morich
Independent Director7.7yrsUS$76.52k0.029%
$ 7.4k
Peter Kiener
Independent Director10yrsUS$193.38k0.00037%
$ 96.0
Rafi Ahmed
Member of Scientific & Clinical Advisory Board3.1yrsno datano data
Kenneth Pienta
Member of Scientific & Clinical Advisory Board3.2yrsno datano data
Jill Broadfoot
Independent Directorless than a yearUS$54.27kno data
Patrick Verheyen
Independent Director2.9yrsUS$76.88k0.0084%
$ 2.2k
Abul K. Abbas
Member of Scientific & Clinical Advisory Board5.1yrsno datano data
Anish Suri
Member of Scientific & Clinical Advisory Board2.2yrsUS$1.18m0.042%
$ 10.9k
Pasha Sarraf
Independent Chairman of the Board1yrUS$88.08k0.33%
$ 86.1k
Michael Kalos
Member of Scientific & Clinical Advisory Board5.1yrsno datano data
3.2yrs
Average Tenure
64yo
Average Age

Experienced Board: CUE's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/22 14:27
End of Day Share Price 2026/03/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cue Biopharma, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Madhu KumarBaird
Zhiqiang ShuBerenberg